Document is current
Any future updates will be listed below
-
Authors
Aagaard, Nikolaj
Larsen, Arendse Tange
Aasvang, Eske K.
Meyhoff, Christian S.
- License Information
-
More Information
Article History
Received: 30 May 2022
Accepted: 16 July 2022
First Online: 2 August 2022
Declarations
:
: CSM and EKA have founded a start-up company, WARD247 ApS, with the aim of pursuing the regulatory and commercial activities of the WARD-project. WARD247 ApS has obtained license agreement for any WARD-project software and patents. One patent has been filed: “Wireless Assessment of Respiratory and circulatory Distress (WARD)—Clinical Support System (CSS)—an automated clinical support system to improve patient safety and outcomes”. None of the above entities have influence on the study design, conduct, analysis, or reporting. CSM also reports direct and indirect research funding from Merck, Sharp & Dohme Corp. and Boehringer Ingelheim outside the submitted work as well as lecture fees from Radiometer. EKA reports institutional research funding from Norpharma, and advisory board work with GenEdit and Concentric Analgesics outside the submitted work and lecture fees from Radiometer. ATL has received research funding from Innovation Fund Denmark as part of a PhD program under the WARD-project.
: Ethical approval and informed consent from participants were not required for this review.
